Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Secarna MD On Standing Out In A Crowd

Secarna's managing director Jonas Renz talks about the company's antisense platform and partnering strategy.

StartUps and SMEs Strategy

UCB Spinout Syndesi Brings New Approach To Dementia

Emerging Company Profile: Syndesi Therapeutics, a new biotech built upon research from UCB, aims to develop novel drugs for neurodegenerative conditions like Alzheimer's disease; the company has a stream of big name investors such as J&J Innovation and Novo Holdings.

StartUps and SMEs Neurology

Genentech BD Director Reviews Recent Technology Deals

Mark Rowan, associate director of business development at Genentech, talks to Scrip at BIO-Europe Spring 2018 about the company's recent technology deals with DiCE Molecules and FinnGen.

Research and Development Strategies StartUps and SMEs

What J&J Gets Out Of JLABS Incubators

Kara Bortone, head of Johnson & Johnson Innovation's JLABS site in San Diego and interim head of the group's newest incubator site in Belgium, on the benefits of JLABS for the companies involved and the big pharma itself.

StartUps and SMEs Strategy

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead precision cancer therapy into Phase II – an asset it licensed from Bristol-Myers Squibb.

Cancer Business Strategies

Herantis CEO Outlines Development Plan For Parkinson's Drug

Pekka Simula, CEO of Herantis, a company born from the merger of Hermo Pharma and Laurantis Pharma, talks to Scrip about the group's lead asset in Parkinson's disease.

StartUps and SMEs Strategy
See All